AUTHOR=Kummer Marvin , El-Battrawy Ibrahim , Gietzen Thorsten , Ansari Uzair , Behnes Michael , Lang Siegfried , Zhou Xiaobo , Borggrefe Martin , Akin Ibrahim 

TITLE=The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 11 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00681

DOI=10.3389/fphar.2020.00681

ISSN=1663-9812

ABSTRACT=Background Takotsubo syndrome (TTS) and acute coronary syndrome (ACS) patients have a similar mortality rate. In this study, we sought to determine the short- and long-term outcome of TTS patients as compared to ACS patients both treated with beta-blockers.

Objectives In the present study we described the data of 5 years of follow up of 103 TTS and 422 ACS patients both treated with beta-blockers. 

Methods Data from TTS patients were included retrospectively and prospectively, ACS patients were included retrospectively. All retrospectively included patients have been followed up for five years. The end point in this study was the occurrence of death. 

Results TTS affected significantly more women (87.4%) than ACS (34.6%) (p < 0.01). TTS patients suffered significantly more often from thromboembolic events (14.6% versus 2.1%; p < 0.01) and cardiogenic shock (11.9% versus 3.6%; p < 0.01) than the ACS group. TTS patients had a significantly higher long-term mortality (within 5 years) as compared to ACS patients (17.5% versus 3.6%) (p < 0.01).Patients of the TTS group compared to the ACS group did not benefit from combination of beta-blockers and ACE-inhibitors in terms of long-term mortality (p < 0.01). As we compare TTS patients who were treated with beta-blockers and ACE-inhibitors versus single use of beta-blockers there was no difference in long-term mortality (p = 0.918). 

Conclusion Takotsubo syndrome patients had a significantly higher long-term mortality (within 5 years) than patients with an acute coronary syndrome.